Jazz Pharmaceuticals (JAZZ) Stock Analysis

November 11, 2026

This is a peer-relative look at Jazz Pharmaceuticals (JAZZ): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Jazz Pharmaceuticals (JAZZ)
Profile Item	JAZZ
Name	Jazz Pharmaceuticals plc
Country/Region	Ireland
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals
GICS Sub-Industry	Pharmaceuticals
Market Capitalization	15.07 billion USD
Currency	USD
Exchange	Nasdaq
Listing Date	June 1, 2007
Security Type	Common Stock

Price Performance

Cumulative Growth

JAZZ

GSPC

Jazz Pharmaceuticals (JAZZ) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Jazz Pharmaceuticals (JAZZ) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Jazz Pharmaceuticals (JAZZ) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Jazz Pharmaceuticals (JAZZ) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: JAZZ	Industry group median
Total Return (1Y)	84.44%	24.62%
Total Return (3Y, Annualized)	27.57%	20.37%
Total Return (5Y, Annualized)	12.88%	-4.02%

Risk Profile

Drawdown History

JAZZ

GSPC

Jazz Pharmaceuticals (JAZZ) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Jazz Pharmaceuticals (JAZZ) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Jazz Pharmaceuticals (JAZZ) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: JAZZ	Industry group median
Volatility (1Y, Annualized)	38.74%	66.36%
Beta (5Y)	0.33	0.93
Max Drawdown (5Y)	-42.03%	-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. JAZZ is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Jazz Pharmaceuticals (JAZZ) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: JAZZ	Industry group median
Sharpe Ratio (1Y)	2.07	0.36
Sortino Ratio (1Y)	4.14	0.58

Profitability

ROE (TTM)

Jazz Pharmaceuticals (JAZZ) posts ROE of 5.05%, roughly around the peer group’s normal range. Shareholders’ equity is producing a return that looks broadly typical for the industry.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.05%

Group distribution

Max: 109.18%
Q3: 6.23%
JAZZ: 5.05%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Largest peers

LLY: 86.02%
NVS: 24.33%
AZN: 22.57%
JNJ: 20.02%
MRK: 5.06%
JAZZ: 5.05%
ABBV: --

Where Jazz Pharmaceuticals (JAZZ) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Jazz Pharmaceuticals (JAZZ) keeps 4.37% of revenue as net profit, roughly in line with the peer group’s normal net margin range. Its full cost stack is taking a typical share of sales for the industry.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.37%

Group distribution

Max: 18.05%
Q3: 4.78%
JAZZ: 4.37%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Largest peers

LLY: 31.90%
AZN: 17.68%
NVS: 17.49%
JNJ: 16.20%
ABBV: 15.67%
JAZZ: 4.37%
MRK: 3.64%

Where Jazz Pharmaceuticals (JAZZ) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Jazz Pharmaceuticals (JAZZ) turns 30.17% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.17%

Group distribution

Max: 83.12%
JAZZ: 30.17%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Largest peers

LLY: 53.66%
ABBV: 39.59%
MRK: 35.22%
NVS: 34.27%
JAZZ: 30.17%
AZN: 29.57%
JNJ: 25.74%

Where Jazz Pharmaceuticals (JAZZ) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Jazz Pharmaceuticals (JAZZ) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: JAZZ	Industry group median
ROE (TTM)	5.05%	-26.66%
ROA (TTM)	6.92%	-12.50%
Net Margin (TTM)	4.37%	0.00%
Operating Margin (TTM)	30.17%	0.00%
Gross Margin (TTM)	91.10%	37.87%

Growth

Revenue Growth

Jazz Pharmaceuticals (JAZZ) grew revenue 4.88%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

Jazz Pharmaceuticals (JAZZ): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

Jazz Pharmaceuticals (JAZZ) grew earnings per share -167.51%, in the lower peer quartile. Per-share profits are advancing more slowly than at most peers, so margins, costs, or share count deserve a closer look.

Jazz Pharmaceuticals (JAZZ): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

Jazz Pharmaceuticals (JAZZ) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: JAZZ	Industry group median
Revenue Growth (YoY)	4.88%	11.45%
Revenue Growth (3Y CAGR)	5.26%	9.94%
EPS Growth (YoY)	-167.51%	4.28%
EPS Growth (3Y CAGR)	--	4.17%

Financial Strength

Current Ratio (MRQ)

Jazz Pharmaceuticals (JAZZ) has current ratio of 1.82, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.82

Group distribution

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
JAZZ: 1.82
Min: 0.10

Largest peers

JAZZ: 1.82
LLY: 1.39
MRK: 1.35
JNJ: 1.02
AZN: 1.01
NVS: 0.88
ABBV: 0.87

Where Jazz Pharmaceuticals (JAZZ) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Jazz Pharmaceuticals (JAZZ) has debt-to-equity ratio of 1.35, in the higher-leverage quartile for its industry. The heavier reliance on borrowing can make earnings, rates, or refinancing conditions matter more.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Group distribution

Max: 1.42
JAZZ: 1.35
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Largest peers

JAZZ: 1.35
NVS: 1.29
LLY: 1.23
MRK: 1.20
AZN: 0.66
JNJ: 0.55
ABBV: --

Where Jazz Pharmaceuticals (JAZZ) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Jazz Pharmaceuticals (JAZZ) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: JAZZ	Industry group median
Current Ratio (MRQ)	1.82	5.52
Debt / Equity (MRQ)	1.35	0.15
Net Debt / EBITDA	1.39	1.08

Dividends

Dividend Yield (TTM)

Jazz Pharmaceuticals (JAZZ) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

JAZZ: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.88%
ABBV: 2.40%
MRK: 2.29%
JNJ: 1.94%
AZN: 1.73%
LLY: 0.49%
JAZZ: 0.00%

Where Jazz Pharmaceuticals (JAZZ) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Jazz Pharmaceuticals (JAZZ) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

JAZZ: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 343.43%
ABBV: 117.35%
NVS: 90.46%
JNJ: 80.12%
AZN: 45.38%
LLY: 21.71%
JAZZ: 0.00%

Where Jazz Pharmaceuticals (JAZZ) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Jazz Pharmaceuticals (JAZZ) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: JAZZ	Industry group median
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Jazz Pharmaceuticals (JAZZ) trades at P/E ratio of 69.46, in the richer earnings-multiple quartile for its industry. That premium needs support from growth, durable earnings, or stronger business quality.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

69.46

Group distribution

Max: 85.34
JAZZ: 69.46
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Largest peers

MRK: 148.21
JAZZ: 69.46
ABBV: 50.05
LLY: 43.95
JNJ: 41.92
NVS: 31.02
AZN: 26.37

Where Jazz Pharmaceuticals (JAZZ) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Jazz Pharmaceuticals (JAZZ) trades at 3.19 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.19

Group distribution

Max: 58.18
Q3: 25.77
Median: 7.30
JAZZ: 3.19
Q1: 3.01
Min: 0.01

Largest peers

LLY: 13.95
ABBV: 7.80
JNJ: 6.69
MRK: 5.37
NVS: 5.35
AZN: 4.63
JAZZ: 3.19

Where Jazz Pharmaceuticals (JAZZ) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Jazz Pharmaceuticals (JAZZ) trades at 3.59 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.59

Group distribution

Max: 13.53
Q3: 6.54
JAZZ: 3.59
Median: 3.25
Q1: 1.69
Min: -5.59

Largest peers

LLY: 29.96
NVS: 8.25
JNJ: 8.16
MRK: 8.06
AZN: 5.59
JAZZ: 3.59
ABBV: -112.34

Where Jazz Pharmaceuticals (JAZZ) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Jazz Pharmaceuticals (JAZZ) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: JAZZ	Industry group median
P/E Ratio (TTM)	69.46	26.69
P/S Ratio (TTM)	3.19	7.30
P/B Ratio (MRQ)	3.59	3.25
Free Cash Flow Yield (TTM)	11.16%	-1.66%